Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Immediate Post-Treatment Care, Aging Mid-Face, Aging

In brief

ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.

Key facts

Study ID

NCT07718347

Run by

Lynch Regenerative Medicine

People needed

21

Starts

2026-04-16

Expected to finish

2027-02-01

Last updated by the study team

2026-07-21

Who can join

Age: 40 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• :Adults 40-65 70 years
• Glogau III-IV
• Fitzpatrick II-IV.
• Suitable for ablative laser
• non-smoker ≥ 3 years
• Willing to comply with post-procedure regimen
• patient reported outcome documentation, and photo documentation.

You may not qualify if…

• Fitzpatrick I or > IV,
• recent facial procedures (< 6 months)
• active skin disease
• pregnancy/lactation
• implanted devices
• history of keloids.

Where it is running

• Laser & Skin Surgery Medical Group — Sacramento, California, United States (enrolling)
• The Practice of Brian S. Biesman, MD — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.